Follow-On Biologics Pathway Unlikely Without Confirmed FDA Commissioner
Executive Summary
FDA is unlikely to proceed with developing a follow-on biologics pathway until a permanent commissioner is confirmed, a Senate Health Committee staffer said at a Food & Drug Law Institute conference in Washington, D.C., Nov. 16
You may also be interested in...
Von Eschenbach’s FDA Will Be A “Facilitating Agency,” Nominee Says
FDA Commissioner-nominee Andrew von Eschenbach plans to use the agency as an engine to help drive product development
Drug Safety Stays At Top Of FDA’s Agenda With New Guidances In The Works
Drug safety will remain a primary focus of FDA's guidance development efforts, according to the Center for Drug Evaluation & Research's 2006 guidance agenda
Drug Safety Stays At Top Of FDA’s Agenda With New Guidances In The Works
Drug safety will remain a primary focus of FDA's guidance development efforts, according to the Center for Drug Evaluation & Research's 2006 guidance agenda